Trump Bought Up to $5 Million of Taser Maker Axon, Two Weeks Before ICE’s $220 Million Order

The post Trump Bought Up to $5 Million of Taser Maker Axon, Two Weeks Before ICE’s $220 Million Order appeared first on 24/7 Wall St..

A CNBC report by Luke Fountain, aired June 29, 2026, walks through a sequence that government watchdogs have flagged and the White House has rejected. President Trump’s Q1 2026 financial disclosures show a purchase of between $1 million and $5 million in shares of Axon Enterprise (NASDAQ:AXON), the top U.S. taser maker.

Two weeks later, U.S. Immigration and Customs Enforcement announced it was looking for vendors on a five-year, $220 million contract to more than quadruple its taser inventory from 4,300 units to almost 18,000. The timing, according to the CNBC report, has drawn scrutiny from ethicists and government watchdogs.

For investors, the headline matters because Axon is already the dominant supplier to U.S. law enforcement, and federal procurement of this size sits squarely inside the growth story management has been selling. The stock opened sharply higher on the news, trading around $513 is up over 10%. Even with that pop, shares are down 38% over the past year from levels last seen in summer 2025.

The purchase, then the procurement

According to Fountain’s reporting, the president’s disclosed AXON purchase landed in Q1 2026, and ICE went public with its tasers solicitation roughly two weeks after. The backdrop for that solicitation is an expanding detainee population.

CNBC notes that ICE detention held a little over 60,000 people in April 2026, up from a little more than 37,000 at the end of fiscal year 2024. A larger detention footprint is a larger addressable market for conducted-energy weapons, body cameras, and the digital evidence platform Axon bundles around them.

Axon itself has not been quiet in Washington. The CNBC piece reports the company spent over $2.4 million lobbying Congress in 2025, its highest in 24 years. Whether that spending touched the ICE process at all is a separate question, and Fountain does not allege it did.

Why experts told CNBC Axon is the front-runner

Fountain’s framing on the competitive landscape is direct. “Experts tell me Axon would be the front runner. It made the tasers currently used by ICE, and the requirements and capabilities outlined by the agency appear to match Axon’s models,” he said on air.

Axon already sells the TASER 10 into federal agencies, runs the evidence.com cloud most departments standardize on, and has been pitching Q1 2026 revenue of over $800 million, up 34% year over year as proof the platform is sticky. Switching costs for a federal customer mid-deployment are real, which is why incumbents tend to win recompetes.

Operationally, Q1 2026 already showed federal momentum. The company reported its strongest quarter on record, with nine consecutive quarters of beating revenue estimates and full-year guidance raised. Analyst price targets sit well above the current quote. RBC Capital reaffirmed Buy with a $735 price target, and the consensus target across covering analysts is $712.75.

The White House denial and what CNBC did not find

The White House told CNBC that “Trump only acts in the best interest of the American public, and there’s no conflict of interest,” adding that the president’s assets are managed by independent third parties with no involvement from Trump or his family.

Fountain explicitly underlined the limits of what reporters had established. “There is no evidence that Trump was involved or had knowledge of the procurement process, that the contracting officials knew about his stock purchase, or that Axon intended to take advantage of Trump buying stock,” he told viewers.

What it means for investors

The CNBC report is careful on that distinction, and so is the framing here. For shareholders, the more durable issue is the one Axon has flagged in its own filings, namely heavy reliance on government budgets and non-appropriation clauses that let agencies walk away.

A $220 million ICE award would feed an already-growing federal book. A delay, or a competitive surprise, would test the thesis. The political conversation is a separate track, and the CNBC piece is the document of record on it.

The post Trump Bought Up to $5 Million of Taser Maker Axon, Two Weeks Before ICE’s $220 Million Order appeared first on 24/7 Wall St..